Please ensure Javascript is enabled for purposes of website accessibility

Why Mylan Is Poised to Keep Popping

By Brian D. Pacampara, CFA - Apr 2, 2013 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this 4-Star.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic pharmaceutical company Mylan (MYL) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Mylan and see what CAPS investors are saying about the stock right now.

Mylan facts

Headquarters (founded)

Canonsburg, Pa. (1961)

Market Cap

$11.4 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$6.8 billion

Management

CEO Heather Bresch
CFO John Sheehan

Return on Equity (average, past 3 years)

14.7%

Cash/Debt

$409.5 million / $5.7 billion

Competitors

Abbott Labs
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.

Earlier this year, one of those Fools, brenoboyle, succinctly summed up the bull case for our community:

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.
MYL
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$113.24 (0.71%) $0.80
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.47 (1.93%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.